The global Wilson’s disease diagnostics market is expected to achieve a valuation of approximately US$ 611.16 million in 2023, with forecasts indicating steady growth over the next decade. The market is projected to accumulate a value of US$ 896 million by 2033, registering a compound annual growth rate (CAGR) of 3.9% during the forecast period from 2023 to 2033. The market demonstrated a CAGR of 3% during the historical period from 2018 to 2022.
The growth of the Wilson’s disease diagnostics market can be attributed to the increasing prevalence of this genetic disorder, characterized by excessive copper accumulation in the body, leading to severe health complications. The rising awareness of Wilson’s disease among healthcare professionals and patients is fostering demand for effective diagnostic solutions.
Key factors contributing to market expansion include the integration of technologically advanced tests and diagnostic tools, such as molecular genetic testing and enhanced imaging techniques, which are improving accuracy and efficiency in diagnosing Wilson’s disease. These advancements enable earlier detection and intervention, significantly impacting patient outcomes.
North America currently dominates the Wilson’s disease diagnostics market, supported by a robust healthcare infrastructure, significant investments in genetic research, and a high level of awareness regarding rare diseases. The Asia-Pacific region is also emerging as a high-growth area, driven by increasing healthcare access, rising incidences of genetic disorders, and growing investments in diagnostic technologies.
As the Wilson’s disease diagnostics market continues to evolve, industry stakeholders are expected to prioritize research and development to introduce innovative diagnostic solutions. The future of the Wilson’s disease diagnostics market appears promising, offering opportunities for improved patient care and advancements in the management of this rare genetic disorder.
Which are Some Prominent Drivers of Wilson’s Disease Diagnostics Market
Growing prevalence and awareness of Wilson’s diseases bolstering market growth
The prevalence of Wilson’s disease is increasing globally, which is driving the demand for diagnostics. According to some estimates, the prevalence of Wilson’s disease is around 1 in 30,000 people worldwide.
Governments in several countries are taking initiatives to promote early diagnosis and treatment of rare diseases like Wilson’s disease. This is driving the growth of the diagnostics market by increasing the availability and accessibility of diagnostic tests.
Market Competition
Key players in the Wilson’s diseases diagnostics market are Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals, Wilson Therapeutics AB
- Orphalan is a medication developed by Swedish Orphan Biovitrum AB (Sobi) for the treatment of Wilson’s disease. Orphalan is a chelating agent that works by binding to excess copper in the body and removing it through the urine. By reducing the amount of copper in the body, Orphalan can help prevent or reduce the severity of symptoms associated with Wilson’s disease, including liver damage, neurological problems, and psychiatric symptoms.
- Vivet Therapeutics is a biotechnology company that is focused on the development of gene therapies for inherited liver disorders, including Wilson’s disease. The company’s lead product candidate, VTX-801, is a gene therapy designed to deliver a functional copy of the ATP7B gene, which is mutated in patients with Wilson’s disease. By providing a functional copy of the gene, VTX-801 aims to restore normal copper metabolism in patients with Wilson’s disease and prevent the accumulation of copper in the liver and other organs.
Key Companies Profiled
- Orphalan
- AstraZeneca
- Vivet Therapeutics
- Pfizer
- Ultragenyx Pharmaceutical
- Valeant Pharmaceuticals International, Inc.
- Noblepharma Co., Ltd.
- Merck & Co., Inc.
- Teva Pharmaceuticals
- Wilson Therapeutics AB
Key Segments Profiled in the Wilson’s Disease Diagnostics Industry Survey
Drug Class:
- Penicillamine
- Trientine
- Tetrathiomolybdate
Route of Administration:
- Oral
- Parenteral
Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
